| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA941: Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) |
|
Medicine details |
|
| Medicine name | ravulizumab (Ultomiris®) |
| Formulation | 300 mg/3 ml and 1,100 mg/11 ml concentrate for solution for infusion |
| Reference number | 5138 |
| Indication | Treatent of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4-seropositive |
| Company | Alexion Pharma UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/12/2023 |
| NICE guidance | |